Evidence map›Paper›PMID 32378810›Full record

ArticleCancer medicine2020

High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.

Jae Wook Lee, Yonggoo Kim, Bin Cho, Seongkoo Kim, Pil-Sang Jang, Jaewoong Lee, Hanwool Cho, Gun Dong Lee, Nack-Gyun Chung, Myungshin Kim

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Jae Wook LeeDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Yonggoo KimDepartment of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID 0000-0003-2808-3795
Bin ChoDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Seongkoo KimDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Pil-Sang JangDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Jaewoong LeeDepartment of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Hanwool ChoDepartment of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Gun Dong LeeCatholic Genetic Laboratory Center, College of Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Nack-Gyun ChungDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Myungshin KimDepartment of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID 0000-0001-8632-0168
Catholic University of Korea · KRSt. Mary's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecent advances in genetic analysis have led to the discovery of novel genetic subtypes of precursor B-cell acute lymphoblastic leukemia (B-ALL) with prognostic relevance. In this study, we studied a cohort of pediatric B-ALL patients to retrospectively determine the incidence of patients harboring novel genetic subtypes, as well as their outcome.

methodsB-ALL patients (N = 190) diagnosed in a single Korean hospital were included in the study. Patients' medical records were reviewed for data on established genetic abnormalities and outcome. CRLF2 expression was analyzed by quantitative RT-PCR. Anchored multiplex PCR-based enrichment was used to detect fusions and point mutations in 81 ALL-related genes.

resultsIncidence of established recurrent genetic subtypes was as follows: high hyperdiploidy (21.6%), ETV6-RUNX1 (21.6%), BCR-ABL1 (7.9%), KMT2A rearrangement (7.4%) TCF3-PBX1/TCF3-HLF (7.4%), and hypodiploidy (1.1%). Incidence of new genetic subtypes was as follows: BCR-ABL1-like (13.2%), ETV6-RUNX1-like (2.1%), EWSR1-ZNF384 (1.1%), and iAMP21 (1.1%). Median age at diagnosis of BCR-ABL1-like ALL was 6.8 years. According to type of genetic abnormality, BCR-ABL1-like ALL was divided into ABL class (12%), CRLF2 class (8%), JAK-STAT class (12%), and RAS class (68%). The 5-year event-free survival (EFS) of BCR-ABL1-like patients was significantly inferior to non-BCR-ABL1-like low- and standard-risk patients (71.5 ± 9.1% vs 92.5 ± 3.2%, P = .001) and comparable to non-BCR-ABL1-like high (75.2 ± 6.2%) and very high-risk patients (56.8 ± 7.4%). All four ETV6-RUNX1-like patients survived event-free.

conclusionAnalogous to previous studies, incidence of BCR-ABL1-like ALL in our cohort was 13.2% with outcome comparable to high and very high-risk patients. A significantly high number of RAS class mutations was a distinct feature of our BCR-ABL1-like ALL group.

Indexed as

MutationAdolescentChildChild, PreschoolCore Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinFusion Proteins, bcr-ablHistone-Lysine N-MethyltransferaseHumansInfantMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionPloidiesPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, CytokineRepublic of KoreaCore Binding Factor Alpha 2 SubunitCRLF2 protein, humanETS Translocation Variant 6 ProteinEWSR1 protein, humanFusion Proteins, bcr-ablHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionReceptors, CytokineRNA-Binding Protein EWSTCF3-HLF fusion protein, humanTCF3-PBX1 fusion protein, humanTEL-AML1 fusion proteinTrans-ActivatorsZNF384 protein, humanacute lymphoblastic leukemiaBCR-ABL1-likeRAS mutation

Identifiers

PMID32378810
PMCPMC7333828
OpenAlexW3022034572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.